About Hemex Health

Hemex Health develops the Gazelle® diagnostic device, a portable platform that utilizes cellulose acetate electrophoresis for the rapid detection of hemoglobin disorders such as sickle cell disease and beta-thalassemia. This device enables front-line healthcare workers to provide accurate and affordable testing in remote settings, facilitating timely medical treatment for at-risk populations.

```xml <problem> Millions worldwide are at risk of inheriting hemoglobin disorders like sickle cell disease and beta-thalassemia, but access to rapid, accurate diagnostic testing at the point of care remains limited, especially in resource-constrained settings. Delayed diagnosis contributes to preventable child deaths and hinders timely medical intervention. </problem> <solution> Hemex Health's Gazelle® is a portable, point-of-care diagnostic platform that enables rapid and affordable detection of hemoglobin disorders. Utilizing a miniaturized version of cellulose acetate electrophoresis, the Gazelle® Hb Variant test identifies hemoglobin disorders in just 8 minutes, displaying hemoglobin percentages by type. Designed for use by front-line healthcare workers with minimal training, the device facilitates accurate testing in remote and challenging environments, empowering timely treatment for at-risk populations. The Gazelle® platform also supports the Gazelle™ Ferritin Test, an easy-to-use assay for measuring ferritin levels using whole blood, serum, or plasma. </solution> <features> - Portable, battery-powered design for point-of-care testing in any environment - Miniaturized cellulose acetate electrophoresis technology for rapid hemoglobin analysis - Results displayed in 8 minutes, including hemoglobin percentages by type - Minimal training required for test administration - Data storage locally or transmission to the Cloud for patient and disease tracking - Gazelle™ Ferritin Test for measuring ferritin levels using whole blood, serum, or plasma (coming soon) </features> <target_audience> The primary target audience includes front-line healthcare workers and providers in remote or resource-limited settings who need rapid, accurate, and affordable diagnostic tools for hemoglobin disorders and ferritin levels. </target_audience> ```

What does Hemex Health do?

When was Hemex Health founded?

Hemex Health was founded in 2016.

How much funding has Hemex Health raised?

Hemex Health has raised 12100000.

Founded

2016

Funding

12100000

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Hemex Health

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

hemexhealth.com LinkedIn Profile

Founded 2016

Funding

Estimated Funding

$10M+

Team

No team information available.

Company Description

Problem

Millions worldwide are at risk of inheriting hemoglobin disorders like sickle cell disease and beta-thalassemia, but access to rapid, accurate diagnostic testing at the point of care remains limited, especially in resource-constrained settings. Delayed diagnosis contributes to preventable child deaths and hinders timely medical intervention.

Solution

Hemex Health's Gazelle® is a portable, point-of-care diagnostic platform that enables rapid and affordable detection of hemoglobin disorders. Utilizing a miniaturized version of cellulose acetate electrophoresis, the Gazelle® Hb Variant test identifies hemoglobin disorders in just 8 minutes, displaying hemoglobin percentages by type. Designed for use by front-line healthcare workers with minimal training, the device facilitates accurate testing in remote and challenging environments, empowering timely treatment for at-risk populations. The Gazelle® platform also supports the Gazelle™ Ferritin Test, an easy-to-use assay for measuring ferritin levels using whole blood, serum, or plasma.

Features

Portable, battery-powered design for point-of-care testing in any environment

Miniaturized cellulose acetate electrophoresis technology for rapid hemoglobin analysis

Results displayed in 8 minutes, including hemoglobin percentages by type

Minimal training required for test administration

Data storage locally or transmission to the Cloud for patient and disease tracking

Gazelle™ Ferritin Test for measuring ferritin levels using whole blood, serum, or plasma (coming soon)

Target Audience

The primary target audience includes front-line healthcare workers and providers in remote or resource-limited settings who need rapid, accurate, and affordable diagnostic tools for hemoglobin disorders and ferritin levels.